The Guardian

AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger

AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-mergerWorldPing

The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling • AstraZeneca shares fall 8.

This is a short WorldPing brief. The full report was published by The Guardian.

Read the full report at The Guardian

Related news

AstraZeneca shares fall 8.9% over merger talks with US cancer drug firmWorldPing
The Guardian

AstraZeneca shares fall 8.9% over merger talks with US cancer drug firm

Proposed $400bn tie-up with Bristol Myers Squibb would create world’s fourth-largest drugmaker but analysts question rationale More than £17bn was wiped off the value of Britain’s biggest drugmaker, AstraZeneca, on Monday after a report that it was i…

Brief by WorldPing · Original reporting by The Guardian

Rolling Stone

More Pop Stars Should Call Ed Sheeran to Write Their Songs

Katseye’s latest single, “Animal,” written by Sheeran, is one of their best — and shows Sheeran knows how to craft a pop hit that sticks, even when it's not for him…

Brief by WorldPing · Original reporting by Rolling Stone